http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103638036-B
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ac31afbea1cbbb03498644721ffb4a62 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_29b632692b06d615bdc9b6031a350b3a |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7048 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-04 |
| filingDate | 2013-11-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2015-03-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_28e619a8094ce91529ea5a01bd79ca52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3188cef52678eacd1cb74d818bb9a001 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_19fc53b471cd4b84f20b90959718eadd http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e6b236ed9ced10eee080462ef4d72143 |
| publicationDate | 2015-03-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-103638036-B |
| titleOfInvention | Application of cardenolide compound in preparation of drugs treating sepsis immunoparalysis |
| abstract | The invention relates to application of a compound with a cardenolide structural parent nucleus in treatment of sepsis immunoparalysis. Plant-derived ouabain is employed in the invention, and experiments show that the compound can obviously reverse the simulating clinical sepsis immunoparalysis mice's survival rate caused by cecal ligation and puncture and salmonella secondary hit, and inhibits the decrease of immunoparalysis mice's spleen and lymph node CD4<+> and CD8<+> cells. In clinical severe sepsis patients' blood mononuclear cells, ouabain can reverse sepsis caused mononuclear cell antigen presentation ability reduction and the expression level reduction of TNF-alpha, GM-CSF, IFN-gamma and other TH1 immunostimulation factors. On an LPS (lipopolysaccharide) induced normal human mononuclear intracellular toxin tolerance model, ouabain can effectively reverse mononuclear TNF alpha expressive ability reduction caused by secondary LPS hit. Drugs for effective treatment of sepsis immunoparalysis are lacked clinically at present. Especially under the circumstance of small molecular drugs, the compound has very good development value and application prospects. |
| priorityDate | 2013-11-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 222.